Thyrocare shares make a decent debut, lists 48% up at Rs 662
The initial public offering (IPO) of Diagnostics company was oversubscribed 73.55 times in a price band of Rs 420-446.
- May 9, 2016,
- Updated May 9, 2016 10:55 AM IST
Shares of Thyrocare made a decent debut on bourses to list at Rs 662 on BSE, a 48.43 per cent premium to its issue price of Rs 446.
The initial public offering (IPO) of Diagnostics company was oversubscribed 73.55 times in a price band of Rs 420-446.
The firm, which runs a diagnostics laboratory chain, has come out with a public issue of up to 10,744,708 shares.
JM Financial Institutional Securities, Edelweiss Financial Services and ICICI Securities managed the issue.
Thyrocare competes with diagnostics chains such as Dr Lal PathLabs, SRL Diagnostics, Metropolis Healthcare and Apollo Clinic.
Many healthcare firms like Alkem Laboratories, Dr Lal PathLabs and Narayana Hrudayalaya came out with their IPOs last year, while HealthCare Global Enterprises got listed on the stock exchanges in March.
Shares of Thyrocare made a decent debut on bourses to list at Rs 662 on BSE, a 48.43 per cent premium to its issue price of Rs 446.
The initial public offering (IPO) of Diagnostics company was oversubscribed 73.55 times in a price band of Rs 420-446.
The firm, which runs a diagnostics laboratory chain, has come out with a public issue of up to 10,744,708 shares.
JM Financial Institutional Securities, Edelweiss Financial Services and ICICI Securities managed the issue.
Thyrocare competes with diagnostics chains such as Dr Lal PathLabs, SRL Diagnostics, Metropolis Healthcare and Apollo Clinic.
Many healthcare firms like Alkem Laboratories, Dr Lal PathLabs and Narayana Hrudayalaya came out with their IPOs last year, while HealthCare Global Enterprises got listed on the stock exchanges in March.